Target-Date Fund (TDF)

A Target-Date Fund (TDF) refers to a type of investment fund commonly offered in employer-sponsored 401(k) plans, designed to simplify retirement savings for participants. Also known as a "Lifecycle Fund" or "Target-Retirement Fund," a TDF is a professionally managed, diversified investment portfolio with an asset allocation strategy that automatically adjusts over time based on the target retirement date of the investor.

The primary objective of a Target-Date Fund is to provide employees with a hands-off approach to retirement investing, tailoring the asset allocation to become more conservative as the target retirement date approaches. This means that younger investors with longer investment horizons will have a higher proportion of equities, which tend to carry higher risk but offer greater growth potential. As employees age and approach retirement, the fund will gradually shift towards a higher allocation of fixed-income assets, such as bonds, to provide more stability and reduced volatility.

Example 1: Suppose an employee plans to retire in 2055. They would select a Target-Date Fund labeled as "2055 Fund" or something similar, which automatically adjusts its asset allocation over time to align with the individual's retirement year.

Example 2: Another employee planning to retire in 2040 would opt for a "2040 Fund." This fund will have a different asset allocation, with a greater emphasis on growth assets since they have a longer investment horizon compared to the first example.

Example 3: A seasoned employee closer to retirement, with a target retirement date of 2023, would select a "2023 Fund" that consists primarily of fixed-income investments to protect their accumulated savings and minimize exposure to market fluctuations as they approach retirement.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.